Cyclerion Therapeutics, Inc. financial data

Symbol
CYCN on Nasdaq
Location
301 Binney Street, Cambridge, MA
State of incorporation
MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 400 % +121%
Return On Equity 28.1 %
Return On Assets 24.1 %
Operating Margin -172 % +94.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.71M shares +12.4%
Common Stock, Shares, Outstanding 2.52M shares +4.49%
Entity Public Float 7.1M USD -62.2%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 2.51M shares +9.99%
Weighted Average Number of Shares Outstanding, Diluted 2.51M shares +9.99%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Research and Development Expense 753K USD -69%
General and Administrative Expense 6.76M USD -29.7%
Operating Income (Loss) -10.8M USD -495%
Nonoperating Income (Expense) 346K USD -12%
Net Income (Loss) Attributable to Parent 3.01M USD +68.4%
Earnings Per Share, Basic 1.63 USD/shares +71%
Earnings Per Share, Diluted 1.63 USD/shares +71%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.59M USD -18.7%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 11K USD -97.4%
Assets, Current 4.72M USD -33.7%
Other Long-term Investments 5.35M USD
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 10.1M USD -0.32%
Accounts Payable, Current 651K USD -65.1%
Liabilities, Current 1.28M USD -74.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -267M USD +1.11%
Stockholders' Equity Attributable to Parent 8.78M USD +70.5%
Liabilities and Equity 10.1M USD -0.32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.87M USD +69.9%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 20M shares 0%
Common Stock, Shares, Issued 2.71M shares +12.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.88M USD +69.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.59M USD -18.7%
Deferred Tax Assets, Valuation Allowance 82.4M USD +0.5%
Deferred Tax Assets, Gross 82.4M USD -0.71%
Property, Plant and Equipment, Gross 126K USD -94.2%
Deferred Tax Assets, Operating Loss Carryforwards 48.5M USD +3.09%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 500K shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 627K USD -82.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares